UPSC Medical Science 2022 — Paper II

Begin with the directive 'enumerate' for part (a), then apply 'outline' for (b) and (c)(iv), 'state/define' for (d)(ii) and (e)(i), and 'describe' for (e)(iii). Allocate approximately 20% time to each of the five main parts (a-e), with sub-part (c) requiring integrated clinical reasoning across its four components. Structure as: (a) tabulated modalities with indications; (b) two-column pharmacological vs non-pharmacological; (c) clinical case synthesis with dehydration assessment; (d) vaccine examples in list format with precise definitions; (e) transmission modes with mite burden specifics and distribution description. No conclusion needed; maximize information density within each marked section.

• (a) Cardiac imaging: ECG, chest X-ray, echocardiography (TTE/TEE), stress testing, cardiac CT, cardiac MRI, nuclear imaging (MUGA, PET), cardiac catheterization with indications for each (e.g., TTE for initial valve assessment, CMR for myocarditis, coronary angiography for CAD)
• (b) Anxiety disorders: Pharmacological (SSRIs first-line, SNRIs, benzodiazepines short-term, buspirone, beta-blockers for somatic symptoms) and non-pharmacological (CBT, exposure therapy, relaxation techniques, lifestyle modifications)
• (c)(i-iv) Pediatric dysentery: Acute bacillary dysentery with some dehydration (WHO Plan B), Shigella flexneri/most commonly S. sonnei in developed settings, complications (hemolytic uremic syndrome, toxic megacolon/septic shock), ORS/zinc/antibiotics (azithromycin/cefixime) with monitoring
• (d) Vaccine types: Capsular polysaccharide (Pneumococcal 23-valent, Meningococcal ACWY), Conjugate (Hib, PCV13, MenACWY-CRM), Recombinant (Hepatitis B, HPV); Herd effect (indirect protection of unvaccinated), Vaccine efficacy (protection in controlled trial vs placebo)
• (e) Scabies: Transmission (direct skin contact, fomites, sexual transmission), mite burden (10-15 in classical initial, rapid increase in reinfection, millions in Norwegian/crusted scabies), distribution (finger webs, wrists, elbows, axillae, periumbilical, groin, buttocks, sparing of head in adults)

This multi-part question requires a structured response across three distinct clinical scenarios. Allocate approximately 40% of time/words to part (a) on adult nephrotic syndrome (20 marks), 30% to part (b) on pediatric pneumonia with its four sub-parts (15 marks), and 30% to part (c) on lichen planus with its three sub-parts (15 marks). Begin each part with clear headings, use bullet points for sub-parts (b)(i)-(iv) and (c)(i)-(iii), and ensure clinical reasoning is explicit throughout.

• Part (a): Etiology of adult nephrotic syndrome distinguishing primary (minimal change disease, FSGS, membranous nephropathy, MPGN) vs secondary causes (diabetes, amyloidosis, SLE, infections, drugs); clinical features emphasizing edema, proteinuria >3.5g/day, hypoalbuminemia, hyperlipidemia; diagnosis including urine analysis, 24-hour urine protein, serum albumin, lipid profile, renal biopsy indications; treatment with ACE inhibitors, steroids, immunosuppressants, and complications management
• Part (b)(i): Complete diagnosis as Measles complicated by severe pneumonia (likely bacterial superinfection) with respiratory distress, recognizing the 7-day interval between measles rash and current presentation as characteristic of measles-associated immune suppression
• Part (b)(ii): Three most important complications: respiratory failure/ARDS, bacterial superinfection (Staphylococcus aureus, Streptococcus pneumoniae, H. influenzae), and measles croup/subglottic obstruction; or alternatively sepsis, empyema, or heart failure
• Part (b)(iii): Severity assessment using WHO IMCI criteria or PAEDIATRIC RISK OF MORTALITY (PRISM) score, specifically noting danger signs: SpO₂ <90%, chest indrawing, nasal flaring, RR >70/min in <2 months (or >60 in 2-12 months), inability to feed, altered consciousness
• Part (b)(iv): Management including oxygen therapy (target SpO₂ >92%), IV antibiotics (ampicillin/ceftriaxone ± gentamicin or vancomycin if MRSA suspected), bronchodilators, hydration, nutrition support, measles vitamin A supplementation, and possible ICU referral for respiratory failure
• Part (c)(i): Four 'P's of lichen planus - Pruritic, Purple, Polygonal, Papules/Plaques (sometimes including fifth P: Planar surfaces)
• Part (c)(ii): Common sites: flexor wrists, forearms, ankles, lumbar region, oral mucosa (buccal, tongue, gingiva), scalp (lichen planopilaris), nails, and genitalia
• Part (c)(iii): Koebner phenomenon definition (isomorphic response - appearance of lesions at sites of trauma); associated disorders: psoriasis, lichen planus, vitiligo, molluscum contagiosum, flat warts, Darier disease

The directive 'discuss' requires comprehensive coverage with critical analysis across all sub-parts. Allocate ~40% time/words to part (a) [20 marks], ~30% to part (b) [15 marks], and ~30% to part (c) [15 marks]. Structure: brief introduction on common themes (preventive care, maternal-child health, pediatric dermatology) → systematic coverage of each sub-part with clinical reasoning → concluding synthesis on primary care approach.

• For (a)(i): Dietary advice for T2DM—caloric restriction, low glycemic index foods, DASH/Mediterranean pattern, carbohydrate counting, fiber intake; Exercise—150 min/week moderate aerobic activity, resistance training, hypoglycemia precautions
• For (a)(ii): Acute complications of T1DM—DKA (pathophysiology: insulin deficiency → lipolysis → ketogenesis → metabolic acidosis) and hypoglycemia; management protocols including fluid resuscitation, insulin infusion, potassium replacement, cerebral edema monitoring
• For (b)(i): Assessment of lactation failure—maternal factors (prolactin levels, breast examination for hypoplasia/inversion, hydration/nutrition, psychosocial stress), infant factors (birth weight, gestational age, oral anatomy, suckling assessment, weight gain trajectory)
• For (b)(ii): WHO/UNICEF criteria for correct positioning (head-body alignment, close to mother, nose-to-nipple alignment, supported whole body) and correct attachment (wide mouth, lower lip everted, chin touching breast, more areola visible above)
• For (b)(iii): Sore nipple management—correct technique education, topical purified lanolin, hydrogel dressings, breast shells, treatment of candidiasis/bacterial infection if present, temporary pumping
• For (c)(i)-(ii): Diaper dermatitis—irritant contact type vs. candidal superinfection; clinical features (erythema sparing skin folds for irritant, involvement of folds with satellite lesions for candida); barrier creams (zinc oxide), antifungals (nystatin/clotrimazole), superabsorbent diapers, air exposure

The directive 'outline' demands structured, systematic presentation of facts across all sub-parts. Allocate approximately 40% time/words to part (a) [20 marks], 40% to part (b) [20 marks], and 20% to part (c) [10 marks]. Structure: Begin with direct identification of hypothyroidism in (a)(i), followed by tabulated cardiovascular comparison, then pharmacological management with monitoring protocols; for (b), present IMNCI assessment criteria in algorithmic format with clear classification and treatment protocols; for (c), provide differential diagnosis with Stevens-Johnson syndrome as primary, followed by immediate management steps. Use tables for comparisons and bulleted lists for protocols to enhance clarity.

• Part (a)(i): Correct identification of primary hypothyroidism (Hashimoto's thyroiditis most likely in 25-year-old female) with brief justification based on clinical triad
• Part (a)(ii): Comprehensive tabular comparison of cardiovascular manifestations: hypothyroidism (bradycardia, diastolic hypertension, decreased cardiac output, pericardial effusion, hypercholesterolemia) versus hyperthyroidism (tachycardia, systolic hypertension, increased cardiac output, high-output failure, atrial fibrillation)
• Part (a)(iii): Pharmacological management—levothyroxine for hypothyroidism (dosing, titration); carbimazole/methimazole, propylthiouracil, radioiodine, surgery for hyperthyroidism; monitoring via TSH (primary), FT4, FT3 with target ranges
• Part (b): IMNCI assessment using main symptoms (convulsions, fast breathing, severe chest indrawing, nasal flaring, grunting, bulging fontanelle, pus discharge from ear, umbilical redness, skin pustules, lethargy, reduced feeding, fever/low body temperature); classification criteria for PSBI versus local infection; treatment protocols including referral, antibiotics (ampicillin + gentamicin), supportive care
• Part (c): Differential diagnosis prioritizing Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum (lamotrigine-induced), DRESS syndrome, bullous pemphigoid; management emphasizing immediate drug withdrawal, supportive care, IV fluids, infection prevention, ophthalmology referral, role of corticosteroids

The directive 'outline' demands a structured, systematic presentation of management protocols and clinical reasoning across all five parts. Allocate approximately 20% (10 marks) each to parts (a), (b), (c), (d), and (e), with sub-parts weighted by their mark distribution—e.g., within (a), spend roughly 20% on (i), 40% on (ii), and 40% on (iii). Structure each part as: clinical assessment → diagnostic approach → management steps → complications/prevention. For (e), explicitly cite IAP/NNF or MoHFW guidelines with specific goals like reducing under-5 mortality and malnutrition.

• For (a)(i): Name Trendelenburg test (for SFJ competence) and Perthes test/MODIFIED Perthes test (for deep venous patency); for (a)(ii): List complications—venous eczema, lipodermatosclerosis, ulceration, thrombophlebitis, bleeding; for (a)(iii): Management of venous ulcer—compression therapy (4-layer bandaging), limb elevation, wound debridement, pentoxifylline, skin grafting if needed
• For (b): Acute retention management—urethral catheterization (first attempt), suprapubic catheter if failed; rule out urethral stricture; definitive management—TURP (gold standard for BPH), open prostatectomy if gland >80g, medical therapy (alpha-blockers, 5-ARIs) for poor surgical candidates
• For (c): Postpartum hemorrhage from retained placenta with scarred uterus—resuscitation (IV fluids, blood transfusion), manual removal of placenta under anesthesia, ultrasound to confirm completeness, hysterectomy if placenta accreta/increta with scar rupture, antibiotics and uterotonics
• For (d)(i): OCP contraindications—age >35 with smoking, migraine with aura, history of thromboembolism, breast/liver cancer, severe hypertension, active liver disease, lactation (estrogen-containing pills); for (d)(ii): Female sterilization failure—recanalization, fistula formation, wrong structure ligated; male—recanalization, technical error (incomplete occlusion), spontaneous reanastomosis
• For (e): National guidelines—IYCF (Infant and Young Child Feeding) 2016, early initiation within 1 hour, exclusive breastfeeding 6 months, complementary feeding 6-24 months, continued breastfeeding 2 years; Goals—reduce neonatal mortality, prevent malnutrition, reduce stunting/wasting, improve cognitive development, achieve 90% institutional delivery and early breastfeeding

The directive 'describe' demands comprehensive, structured coverage of clinical entities and processes across all four sub-parts. Allocate approximately 40% of time/words to part (a) given its 20 marks, 30% to part (b) for 15 marks, and 30% combined to (c)(i) and (c)(ii) for 15 marks. Structure as: (a) definition → risk factors → clinical signs → alarming symptoms → management; (b) clinical features → diagnosis → management; (c) objectives → systematic investigation steps. Use Indian epidemiological data (e.g., NFHS-5 for maternal health, RNTCP for TB, IDSP for outbreak investigation) throughout.

• Part (a): Precise definition of pre-eclampsia (new-onset hypertension + proteinuria after 20 weeks); risk factors include nulliparity, chronic hypertension, multiple gestation, renal disease; clinical signs (BP ≥140/90, proteinuria, edema); alarming symptoms (headache, visual disturbances, epigastric pain, hyperreflexia); management per FIGO/WHO guidelines with antihypertensives, magnesium sulfate, delivery timing
• Part (b): Ileo-caecal TB features (abdominal pain, mass, obstruction, alternating constipation-diarrhea); diagnosis via colonoscopy with biopsy (caseating granulomas), CT/MRI showing 'comb sign', ascitic fluid ADA, GeneXpert MTB/RIF; ATT regimen per RNTCP (2HRZE/4HRE) with surgery for complications
• Part (c)(i): Epidemic investigation objectives: verify diagnosis, determine extent, identify source/mode of transmission, implement control, formulate hypotheses, train personnel
• Part (c)(ii): Systematic steps: prepare for field work, establish existence of epidemic, verify diagnosis, define and count cases, orient data by person/place/time, formulate/test hypotheses, implement control measures, communicate findings (reference IDSP outbreak response protocol)
• Integration: Application of Indian public health frameworks (RNTCP, IDSP, MCP) and recent epidemiological data (e.g., rising TB-DM comorbidity, maternal mortality trends)

The directive 'enumerate' demands systematic listing with brief elaboration. Structure: (a) Acute cholecystitis diagnosis with Tokyo guidelines mention, complications in anatomical sequence, Mirizzi with Csendes classification; (b) Iron distribution with diagram, functions categorized, Anaemia Mukt Bharat 6x6x6 strategy; (c) HRT current consensus per NAMS/IMS guidelines, merits/demerits balanced. Allocate ~40% time to 7(a) [20 marks], ~35% to 7(c) [15 marks], ~25% to 7(b) [15 marks].

• 7(a)(i): Diagnosis of acute calculous cholecystitis per Tokyo Guidelines 2018 (TG18) with Murphy's sign, ultrasound findings; management—IV antibiotics (ceftriaxone + metronidazole), analgesia, early laparoscopic cholecystectomy vs. delayed based on severity
• 7(a)(ii): Complications classified as intra-luminal (mucocele, empyema), extra-luminal (perforation, peritonitis, abscess), fistulous (cholecystoenteric, gallstone ileus), and malignant (GB cancer)
• 7(a)(iii): Mirizzi syndrome Type I (extrinsic compression) vs Type II-IV (fistula) per Csendes classification; investigation—MRCP (gold standard), ERCP; management—open surgery, subtotal cholecystectomy, Roux-en-Y hepaticojejunostomy for Type IV
• 7(b): Total body iron 3-4g (men) / 2-2.5g (women); 65% in Hb, 30% stores (ferritin/hemosiderin), 5% myoglobin/enzymes; functions—oxygen transport, electron transport (cytochromes), DNA synthesis (ribonucleotide reductase), immune function
• 7(b): Anaemia Mukt Bharat 6 interventions—IF supplementation, deworming, delayed cord clamping, dietary diversification, fortified foods, screening; 6 target groups—children, adolescents, women, pregnant/lactating; 6 institutional mechanisms
• 7(c): Current HRT consensus—'window of opportunity' (age <60 or <10 years post-menopause), transdermal estradiol preferred, lowest effective dose, individualized risk assessment; contraindications—VTE, breast cancer, CVD, stroke, liver disease
• 7(c): Merits—vasomotor symptom relief, osteoporosis prevention, urogenital atrophy improvement, possible cognitive benefit if early initiation; demerits—VTE risk (RR 2-3), breast cancer (RR 1.2 with >5 years use), stroke, gallbladder disease

The directive 'discuss' demands a comprehensive, analytical treatment across all sub-parts. Allocate approximately 40% of time/words to 8(a) End TB Strategy (20 marks), 30% to 8(b) HPV vaccination (15 marks), and 30% to 8(c) breast cancer case (15 marks). Structure: begin with WHO End TB Strategy principles and pillars, transition to HPV vaccines with Indian context (SIIP, Tamil Nadu pilot), conclude with systematic breast cancer workup and MRM anatomy.

• 8(a)(i-iii): End TB Strategy principles (SDG alignment, patient-centered care), three pillars with 13 components, barriers (MDR-TB, stigma, COVID-19 disruption, funding gaps)
• 8(b)(i): India-specific HPV impact data—Tamil Nadu demonstration project, SIIP inclusion, coverage challenges, potential for cervical cancer reduction
• 8(b)(ii): Bivalent (Cervarix: 0, 1-2, 6 months), Quadrivalent (Gardasil: 0, 2, 6 months), Nonavalent (Gardasil 9: same schedule); age groups 9-14 vs 15-26; 2-dose vs 3-dose schedules
• 8(c)(i): Malignant breast lump features—hard, irregular, fixed, skin dimpling/peau d'orange, nipple retraction, bloody discharge, axillary lymphadenopathy
• 8(c)(ii): Triple assessment—clinical examination, imaging (mammography/USG/MRI), cytology/histology (FNAC/core biopsy); receptor status (ER/PR/HER2)
• 8(c)(iii): MRM preservation—pectoralis major, pectoralis minor (or only major in Patey modification), long thoracic nerve (serratus anterior), thoracodorsal nerve (latissimus dorsi), intercostobrachial nerve